CoChat
Sign Up
Cited by 259Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

The effect of bupropion on nicotine craving and withdrawal

Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., DeVeaugh-Geiss, J.·2000·Psychopharmacology
DOI 10.1007/s002130050022
Open this paper in CoChat — free account

Abstract

Rationale and objectives Bupropion has demonstrated efficacy for smoking cessation. Given the importance of nicotine craving and withdrawal in the smoking cessation process, the current study examined the effects of bupropion on these parameters during smoking abstinence. Methods During a 2-day Baseline phase with ad lib smoking, 91 non-depressed smokers (who were not trying to quit permanently) were administered measures of nicotine craving, withdrawal symptoms, and timed measures of cognitive performance five times daily. Participants were then assigned randomly to a 14-day treatment regimen with bupropion 300 mg/day, bupropion 150 mg/day, or placebo. Thereafter, the above measures were re-administered during 3 days of abstinence on a closed research ward. Results Relative to placebo, 300 mg bupropion significantly reduced abstinence-associated increases in rated depression, difficulty concentrating, and irritability, and attenuated a decrease in positive affect. The results also suggested that bupropion might have a positive effect on performance measures during the withdrawal period. No effects were observed on craving, anxiety, restlessness, or hunger. The lack of findings on craving measures may be explained by a floor effect; except on the first day of abstinence, neither drug nor placebo groups showed much craving elevation during abstinence. Conclusions Study results indicate that bupropion ameliorates some nicotine withdrawal symptoms.

Integrity signals

Registry

Crossref · 10.1007/s002130050022

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In nicotine smokers during withdrawal, no differences were detected between bupropion 150-300 mg and placebo.

    “However, when nicotine smokers were examined during withdrawal, no differences were detected between bupropion (150-300mg) and placebo (Shiffman et al., 2000).”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Shiffman et al., 2000

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J.
Affiliations
  • University of Pittsburgh (US)
  • Brown University (US)
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2000-01-21
Volume
148
Issue
1
Pages
33-40
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s002130050022
OpenAlex
W2056579603
Cited by
259
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 1 · 2021: 2 · 2020: 6 · 2019: 6 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 4
FWCI
27.29
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
bupropion, nicotine craving, nicotine withdrawal, smoking cessation, smoking abstinence, depression, cognitive performance, irritability, positive affect, nicotine dependence
MeSH terms
Adult, Double-Blind Method, Female, Humans, Male, Nicotine, Patient Compliance, Psychiatric Status Rating Scales, Psychomotor Performance, Surveys and Questionnaires, Sleep, Smoking, Substance Withdrawal Syndrome, Tobacco Use Disorder, Smoking Cessation, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review